MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.

Animals Cell Line, Tumor Cetuximab / pharmacokinetics Drug Resistance, Neoplasm Enzyme Activation Gene Expression Head and Neck Neoplasms / drug therapy Humans Indoles / pharmacology MAP Kinase Signaling System Mice Mice, Inbred NOD Mice, SCID Proto-Oncogene Proteins c-met / metabolism Random Allocation Receptor, ErbB-2 / antagonists & inhibitors Receptor, ErbB-3 / antagonists & inhibitors Squamous Cell Carcinoma of Head and Neck / drug therapy Sulfones / pharmacology Up-Regulation Xenograft Model Antitumor Assays
MET cetuximab drug resistance head and neck cancer signaling

Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 08 2019
Historique:
received: 23 08 2018
revised: 11 12 2018
accepted: 15 01 2019
pubmed: 30 1 2019
medline: 18 12 2019
entrez: 30 1 2019
Statut: ppublish

Résumé

An understanding of the mechanisms underlying acquired resistance to cetuximab is urgently needed to improve cetuximab efficacy in patients with head and neck squamous cell carcinoma (HNSCC). Here, we present a clinical observation that MET pathway activation constitutes the mechanism of acquired resistance to cetuximab in a patient with HNSCC. Specifically, RNA sequencing and mass spectrometry analysis of cetuximab-sensitive (Cetux

Identifiants

DOI: 10.1002/ijc.32170 PMID: 30694565 PMC: PMC6554031
pubmed: 30694565
doi: 10.1002/ijc.32170
pmc: PMC6554031
mid: NIHMS1017191
doi:

Substances chimiques

5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one 0
Indoles 0
Sulfones 0
ERBB2 protein, human EC 2.7.10.1
ERBB3 protein, human EC 2.7.10.1
MET protein, human EC 2.7.10.1
Proto-Oncogene Proteins c-met EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1
Receptor, ErbB-3 EC 2.7.10.1
Cetuximab PQX0D8J21J

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

748-762

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2019 UICC.

Références

Cancer Discov. 2015 Dec;5(12):1271-81
pubmed: 26432108
Cancer Cell. 2006 Jul;10(1):39-50
pubmed: 16843264
Clin Cancer Res. 2016 Aug 15;22(16):4005-13
pubmed: 27370607
Cell Death Dis. 2016 Oct 27;7(10):e2442
pubmed: 27787520
Anticancer Res. 2015 Oct;35(10):5499-502
pubmed: 26408715
Clin Cancer Res. 2015 May 1;21(9):2157-66
pubmed: 25623215
Science. 2007 May 18;316(5827):1039-43
pubmed: 17463250
Clin Cancer Res. 2011 Aug 1;17(15):5197-204
pubmed: 21653686
Clin Cancer Res. 2006 Sep 15;12(18):5268-72
pubmed: 17000658
Sci Transl Med. 2011 Sep 7;3(99):99ra86
pubmed: 21900593
Hum Pathol. 2012 Apr;43(4):496-505
pubmed: 21855111
Cancer Res. 2013 Oct 1;73(19):6024-35
pubmed: 23928993
Cell. 1994 Apr 22;77(2):261-71
pubmed: 7513258
Cancer Res. 2014 Sep 15;74(18):5152-64
pubmed: 25136066
Clin Cancer Res. 2016 Aug 1;22(15):3961-70
pubmed: 26920888
Oncogene. 2010 Oct 7;29(40):5500-10
pubmed: 20661224
Nature. 2012 Jul 26;487(7408):500-4
pubmed: 22763439
Clin Cancer Res. 2011 Jul 1;17(13):4425-38
pubmed: 21622718
Cancer Res. 2009 Apr 1;69(7):3021-31
pubmed: 19318576
J Clin Oncol. 2007 Jun 1;25(16):2171-7
pubmed: 17538161
Clin Cancer Res. 2009 Jun 1;15(11):3740-50
pubmed: 19470725
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Clin Cancer Res. 2017 May 15;23(10):2414-2422
pubmed: 27780856
Clin Cancer Res. 2017 Feb 1;23(3):677-686
pubmed: 27358485
J Mol Diagn. 2013 Jul;15(4):454-65
pubmed: 23672976
Cancer Res. 2002 Dec 15;62(24):7350-6
pubmed: 12499279
Nat Rev Cancer. 2012 Jan 24;12(2):89-103
pubmed: 22270953
Clin Cancer Res. 2009 Apr 1;15(7):2207-14
pubmed: 19318488
N Engl J Med. 2008 Mar 13;358(11):1160-74
pubmed: 18337605
Cancer Res. 2018 Aug 1;78(15):4331-4343
pubmed: 29792310
Nat Med. 2015 Jul;21(7):795-801
pubmed: 26030179
PLoS One. 2014 Jul 01;9(7):e100586
pubmed: 24983965
Gene. 2006 Jan 17;366(1):2-16
pubmed: 16377102
Cancer Res. 2006 Apr 15;66(8):3992-5
pubmed: 16618717
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Invest New Drugs. 2013 Apr;31(2):417-24
pubmed: 22918720
Cancer Discov. 2014 Nov;4(11):1269-80
pubmed: 25293556
Clin Cancer Res. 2013 Jan 15;19(2):380-92
pubmed: 23213056
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Am J Pathol. 2001 Oct;159(4):1231-8
pubmed: 11583950
J Biol Chem. 2001 Apr 27;276(17):14407-13
pubmed: 11278550
Cancer Cell. 2015 Apr 13;27(4):533-46
pubmed: 25873175
J Transl Med. 2015 Aug 29;13:282
pubmed: 26319934
Oncogene. 2008 Jun 26;27(28):3944-56
pubmed: 18297114
Nature. 2015 Oct 8;526(7572):263-7
pubmed: 26416732
Cell. 2007 Nov 30;131(5):1018
pubmed: 18045542
Ann Oncol. 2012 Apr;23(4):1016-22
pubmed: 21865152
Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
pubmed: 11597398
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5021-6
pubmed: 21385943
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nature. 2007 Jan 25;445(7126):437-41
pubmed: 17206155
Nat Rev Clin Oncol. 2010 May;7(5):251-65
pubmed: 20351699
Cancer Biol Ther. 2011 May 1;11(9):777-92
pubmed: 21293176
Oncotarget. 2016 Sep 6;7(36):57978-57990
pubmed: 27517321
Lancet Oncol. 2012 Jan;13(1):33-42
pubmed: 22056021
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2718-23
pubmed: 21368164
Clin Proteomics. 2012 May 03;9(1):5
pubmed: 22554165
Endocr Relat Cancer. 2001 Mar;8(1):3-9
pubmed: 11350723
Mol Cancer. 2014 Oct 24;13:242
pubmed: 25344208
Cancer Cell. 2012 Feb 14;21(2):227-39
pubmed: 22340595
Mol Oncol. 2016 Jan;10(1):138-147
pubmed: 26422389
Radiother Oncol. 2003 Mar;66(3):253-62
pubmed: 12742264
Eur J Cancer. 2011 May;47(8):1231-43
pubmed: 21273060
Clin Cancer Res. 2006 Sep 1;12(17):5064-73
pubmed: 16951222
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Cancer Discov. 2013 Jun;3(6):658-73
pubmed: 23729478
Cancer Cell. 2011 Jan 18;19(1):58-71
pubmed: 21215704

Auteurs

Ofra Novoplansky (O)

The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Matthew Fury (M)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Manu Prasad (M)

The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Ksenia Yegodayev (K)

The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Jonathan Zorea (J)

The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Limor Cohen (L)

The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Raphael Pelossof (R)

Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Liz Cohen (L)

The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Nora Katabi (N)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Fabiola Cecchi (F)

NantOmics 9600 Medical Center Drive, Rockville, MD.

Ben-Zion Joshua (BZ)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Department of Otolaryngology - Head and Neck Surgery, Soroka University Medical Center, Beer-Sheva, Israel.

Aron Popovtzer (A)

Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel.
The Head and Neck Cancer Radiation Clinic, Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.

Jose Baselga (J)

Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

Maurizio Scaltriti (M)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
ORCID: 0000-0002-5522-1447

Moshe Elkabets (M)

The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
ORCID: 0000-0003-3634-9098

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › MET activation confers resistance to...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › MET activation confers resistance to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Cétuximab › MET activation confers resistance to...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › MET activation confers resistance to...
questionsmedicales.fr › Métabolisme › Activation enzymatique › MET activation confers resistance to...
questionsmedicales.fr › Phénomènes génétiques › Expression des gènes › MET activation confers resistance to...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › MET activation confers resistance to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › MET activation confers resistance to...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Indoles › MET activation confers resistance to...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Système de signalisation des MAP kinases › MET activation confers resistance to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › MET activation confers resistance to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée NOD › MET activation confers resistance to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris SCID › MET activation confers resistance to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-met › MET activation confers resistance to...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Répartition aléatoire › MET activation confers resistance to...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › MET activation confers resistance to...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-3 › MET activation confers resistance to...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Carcinome épidermoïde de la tête et du cou › MET activation confers resistance to...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Sulfones › MET activation confers resistance to...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation positive › MET activation confers resistance to...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › MET activation confers resistance to...